Galera Therapeutics Q1 net loss $17.7M; avasopasem NDA gets FDA priority review with PDUFA Aug 9

Galera Therapeutics, Inc.

2023-Q1 EPS reported -$0.50 vs consensus -$0.39 ▼ miss (-28.2%)

Net loss of $17.7M ($0.50 per share) in Q1 2023 vs $15.4M ($0.58 per share) in Q1 2022.
Cash, cash equivalents and short-term investments of $47.8M as of March 31, 2023; expected to fund operations into Q4 2023.
FDA granted priority review for avasopasem NDA for radiotherapy-induced severe oral mucositis; PDUFA date August 9, 2023.
Raised $30M gross proceeds from registered direct offering in February 2023.
Expanded commercial leadership team with three new VPs in preparation for potential U.S. launch.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Galera Therapeutics, Inc. reported financial results for quarter ended March 31, 2023.

Period: quarter ended March 31, 2023
Result: reported results

Exact text from the filing

On May 11, 2023, Galera Therapeutics, Inc. announced its financial results for the quarter ended March 31, 2023.

View on SEC.gov

36 earnings releases filed in the last 30 days. Browse all earnings releases →

Galera Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-141380

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.